Shares of Merck KGaA (OTCMKTS:MKGAY – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company.
MKGAY has been the subject of a number of research reports. HSBC initiated coverage on Merck KGaA in a research note on Friday, July 14th. They set a “buy” rating for the company. Stifel Nicolaus initiated coverage on Merck KGaA in a research note on Thursday, July 6th. They set a “buy” rating for the company.
Merck KGaA Price Performance
Shares of MKGAY stock opened at $38.36 on Monday. Merck KGaA has a 12-month low of $32.53 and a 12-month high of $42.02. The business has a 50 day simple moving average of $38.36 and a 200 day simple moving average of $38.36.
Merck KGaA Company Profile
Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility.
Further Reading
- Five stocks we like better than Merck KGaA
- How to evaluate dividend stocks before buying
- MarketBeat Week in Review – 7/24 – 7/28
- How to Invest in Casino Stocks
- Can SAIA Continue its Stratospheric Rally?
- What is ChatGPT Stock? How to Invest in It
- Why Markets Are Loving Exxon Mobil, Despite The Earnings Dip
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
